A new study released in the Journal of the American Pharmaceutical Association (vol. 41, no. 2) estimates that drug misuse costs the economy more than $177 billion each year. And, according to the study, the estimated number of patient deaths resulting from misuse of prescription drugs has increased from 198,000 in 1995 to 218,000 in 2000.
A new study released in the Journal of the American Pharmaceutical Association (vol. 41, no. 2) estimates that drug misuse costs the economy more than $177 billion each year. And, according to the study, the estimated number of patient deaths resulting from misuse of prescription drugs has increased from 198,000 in 1995 to 218,000 in 2000.
The study, "Drug-Related Morbidity and Mortality: Updating the Cost-of-Illness Model," was conducted by Frank R. Ernst and Amy J. Grizzle of the College of Pharmacy, University of Arizona, Tucson.
According to the authors, "Researchers have shown that costs associated with drug-related problems exceed the expenditures for initial drug therapy; that is, the total cost of drug-related morbidity and mortality exceeds the cost of medications themselves. Drug-related problems are increasingly recognized as a serious and urgent - but largely preventable - medical problem."
Among the most significant drug-related problems identified in the JAPhA study are untreated indication, improper drug selection, subtherapeutic dosage, failure to receive drugs, overdosage, adverse drug reactions, drug interactions and drug use without indication.
The new research updates a 1995 study, published in the Archives of Internal Medicine, that was conducted by Jeffrey A. Johnson and J. Lyle Bootman of the College of Pharmacy, University of Arizona. That study estimated the annual cost of morbidity and mortality resulting from drug-related problems in the ambulatory setting at $76.6 billion.
Of the $177.4 billion in yearly costs estimated by the new study, hospital admissions accounted for $121.5 billion (69%), and long-term care admissions represented $32.8 billion (18%). Physician visits accounted for another $13.8 billion (8%), and emergency department visits and additional treatment cost more than $5.8 billion (3%) and $3.5 billion (2%), respectively.
The majority of cost increases appeared to result from hospital and long-term care admission costs, which, according to estimates in the literature, were more than twice the 1995 estimates. The data revealed that the greatest increases in drug-related morbidity and mortality costs were in total hospital admissions (2.6 times), total long-term care admissions (2.3 times) and total physician visits (1.9 times). These events contributed the most to the total cost of illness estimate of $177.4 billion.
The authors of the study wrote, "Drug-related morbidity and mortality continue to pose a serious medical and economic problem for society. More attention should be directed toward developing solutions that reduce preventable morbidity, mortality, and costs associated with drug-related problems." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
AbbVie’s Emraclidine Fails to Reduce Schizophrenia Symptoms Compared to Placebo
November 11th 2024Results from the Phase II EMPOWER trial found that emraclidine failed to meet its primary endpoint of reducing Positive and Negative Syndrome Scale scores after six weeks of treatment for schizophrenia.